NiKang Therapeutics
3 known investors
NiKang Therapeutics is a clinical-stage biotech company developing small molecule drugs for cancer treatment, focusing on HIF2α, CDK2, and KRAS targets using structure-based drug design.
Biotech
Investors · 3
In the news
- NiKang Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2022
- NiKang Therapeutics - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2022
- Wilmington's NiKang Therapeutics closed a $200M Series Ctechnical.ly · 2021
- Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPOendpoints.news · 2021
- NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targetsbusinesswire.com · 2021
- NiKang's new CFO appointment pays off with $200M fund raise from her previous employer | Fierce Biotechfiercebiotech.com · 2021